Navigation Links
Protein Sciences Prepared to Combat the Latest Potential Pandemic Flu Virus
Date:5/2/2013

MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine.

It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary, recombinant technology that enables us to develop vaccines for potentially deadly viruses without the use of a live disease virus and, therefore, without any risk to personnel.

We could manufacture the vaccine in our Pearl River, NY facility that we leased from Pfizer in November 2012.  In just 100 days we have been able to renovate the facility, restore it to full operating condition for our technology and manufacture three lots of antigens for our seasonal influenza vaccine, Flublok® that was approved by the FDA in January 2013.  Significant help in the process has been obtained from the State of New York and Rockland County and from current and former Pfizer personnel who have been incredibly helpful and supportive.

Manon Cox , President and CEO of Protein Sciences said, "We are excited that we have been able to move so quickly on the H7N9 vaccine.  We have consistently been first to have vaccines for potential pandemics, including manufacturing the first pandemic vaccine in 1997-98 in response to the Hong Kong Bird Flu.  We are very grateful for support from the Centers for Disease Control and Prevention who provided us with a killed H7N9 virus that allowed us to start the process."  She added, "Our Pearl River manufacturing facility has sufficient capacity to allow us to manufacture more than twice the number of doses of pandemic influenza vaccine in a six month period than is required by our contract with the Biomedical Advanced Research and Development Authority (BARDA)."

About Us

Protein Sciences Corporation is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals.  

On January 16, 2013, the U.S. FDA approved Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, for use in adults 18-49 years old. 

Flublok and its sister vaccine, Panblok®, that is designed to protect against pandemic influenza, have been developed in partnership with BARDA through Contract No. HHS0100200900106C. 

Learn more at www.proteinsciences.com and www.flublok.com.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
2. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
3. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
4. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
5. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
6. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
7. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
8. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
9. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
10. ProteinSimple Charges Ahead with the Simple Western
11. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test para el mercado ... Continue Reading ... New: INSTI Self Test! ... , bioLytical Laboratories (la "Compañía"), un líder mundial ... lanzamiento de su INSTI HIV Self Test  a África con una versión de ...
(Date:12/2/2016)... According to the latest market report published by ... Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type Segment Anticipated ... the global automated endoscope reprocessors market was valued at US$ 740.6 Mn ... of 7.2% during an eight-year forecast period 2016-2024, to reach ... ...
(Date:12/2/2016)... , Dec. 2, 2016 In the ... sources apart from those derived from C. sativa, the ... Universita` di Napoli Federico II , the Universita` ... the first comprehensive, critical, integrated and unified inventory of ... article focuses on the remarkable chemical and structural ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to host ... other developmental disabilities. The group, which is being launched with the help of Robbie ... share stories and advice, seek help, and continue their education on how to best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... Cleveland, OH (PRWEB) , ... December 02, 2016 ... ... provider of veterinarian diagnostic imaging systems and the first company to ... Robot With a Heart at their tradeshow booth # 941 for the American ...
(Date:12/2/2016)... ... 02, 2016 , ... Clarify Health Solutions, Inc., the leading ... in an initial round of funding. The round was led by experienced investors ... receive far better care through the application of the best technologies from other ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... to announce that we have been designated as a Cigna Infertility Center of ... exceed rigorous performance standards. , “It’s an honor to be designated a ...
Breaking Medicine News(10 mins):